Enzo Biochem, Inc.  

(Public, NYSE:ENZ)   Watch this stock  
Find more results for ENZ
7.48
+0.21 (2.89%)
After Hours: 7.48 0.00 (0.00%)
Dec 8, 4:39PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 7.13 - 7.50
52 week 4.00 - 7.50
Open 7.22
Vol / Avg. 294,419.00/171,551.00
Mkt cap 354.95M
P/E 7.73
Div/yield     -
EPS 0.97
Shares 46.28M
Beta 1.46
Inst. own 63%
Dec 9, 2016
Q1 2017 Enzo Biochem Inc Earnings Call - 8:30AM EST - Add to calendar
Dec 8, 2016
Q1 2017 Enzo Biochem Inc Earnings Release
Oct 14, 2016
Q4 2016 Enzo Biochem Inc Earnings Call - Webcast
Oct 13, 2016
Q4 2016 Enzo Biochem Inc Earnings Release
Sep 12, 2016
Enzo Biochem Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '16) 2016
Net profit margin 135.83% 44.06%
Operating margin 140.67% 45.73%
EBITD margin - -0.02%
Return on average assets 153.94% 50.26%
Return on average equity 203.39% 68.53%
Employees 446 -
CDP Score - -

Address

60 EXECUTIVE BLVD
FARMINGDALE, NY 11735
United States - Map
+1-516-7555500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Officers and directors

Barry W. Weiner President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elazar Rabbani Ph.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 72
Bio & Compensation  - Reuters
James M. O'Brien Executive Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
David C. Goldberg Vice President - Corporate Development, General Manager of Enzo Clinical Labs
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dieter Schapfel M.D. Chief Medical Director
Age: 52
Bio & Compensation  - Reuters
Bernard L. Kasten Jr., M.D. Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Gregory M. Bortz Independent Director
Age: 46
Bio & Compensation  - Reuters
Dov Perlysky Independent Director
Age: 53
Bio & Compensation  - Reuters